Premium
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG‐GO) as front‐line regimen in patients with core binding factor acute myelogenous leukemia
Author(s) -
Borthakur Gautam,
Cortes Jorge E.,
Estey Elihu E.,
Jabbour Elias,
Faderl Stefan,
O'Brien Susan,
GarciaManero Guillermo,
Kadia Tapan Mahendra,
Wang Xuemei,
Patel Keyur,
Luthra Rajyalakshmi,
Koller Charles,
Brandt Mark,
Ravandi Farhad,
Kantarjian Hagop
Publication year - 2014
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.23795
Subject(s) - flag (linear algebra) , gemtuzumab ozogamicin , cytarabine , fludarabine , medicine , granulocyte colony stimulating factor , regimen , front line , leukemia , oncology , immunology , chemotherapy , cd33 , biology , stem cell , mathematics , cd34 , pure mathematics , genetics , algebra over a field , cyclophosphamide , political science , law
Despite being considered “good‐risk” acute myelogenous leukemia (AML), long term outcomes in core binding factor (CBF) AML suggest room for improvement. We report on a regimen consisting of fludarabine, cytarabine, granulocyte colony stimulating factor, and low dose gemtuzumab ozogamicin (FLAG‐GO) as front‐line therapy of patients with CBF AML. Forty‐five patients were enrolled (median age 48 years). Remission rate was 95% with 5% induction deaths. The overall survival (OS) and relapse free survival (RFS) probability at 3 years are 78% and 85%, respectively. FLAG‐GO regimen results in high rates of RFS and OS in CBF AML. Our data along with recent data from several large groups strongly argues in favor of incorporation of gemtuzumab ozogamicin in frontline regimens for CBF AML. Am. J. Hematol. 89:964–968, 2014. © 2014 Wiley Periodicals, Inc.